(B)Tofacitinib
10 mg BID
EULAR response, n/N (%)
 Good2/13 (15.4%)
 Moderate9/13 (69.2%)
 None2/13 (15.4%)
ACR response, n/N (%)
 ACR206/13 (46.2%)
 ACR505/13 (38.5%)
 ACR702/13 (15.4%)

  • ACR, American College of Rheumatology; BID, twice daily; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism.